AIMS: Gastric inhibitory polypeptide (GIP) is an insulinotropic duodenal hormone released in response to meals. Recent studies in rodents suggested that GIP directly links overnutrition to obesity. Despite evidence for GIP effects on fat metabolism in humans, the GIP receptor (GIPR) has not been identified in fat tissues. We identified the GIPR gene in human subcutaneous and visceral fat tissues and tested the hypothesis that that the expression of this gene is influenced by central obesity and weight loss. METHODS: GIPR gene mRNA expression in subcutaneous fat tissue biopsies (n=70) and in paired subcutaneous and visceral fat tissue samples (n=25) of non-diabetic postmenopausal women was studied by real-time reverse transcription polymerase chain reaction. The effect of weight reduction on GIPR gene expression in subcutaneous fat tissue was studied in a subset of 14 women. RESULTS: GIPR adipose tissue gene expression was significantly lower in insulin resistant obese non-diabetic women (p=0.004). The GIPR mRNA expression was higher in the visceral fat tissue compared with subcutaneous fat (p<0.001). Despite adjustment for obesity-associated variables, waist circumference was the most significant predictor of GIPR gene expression in subcutaneous fat depot (F=4.066; beta=-0.997; p=0.0001) and, together with fasting insulin levels, in visceral fat (F=3.553; beta=-0.507 and beta=0.495; p=0.0001). Moderate weight reduction did not change gene expression levels of the GIPR gene (p=0.085). CONCLUSIONS: Decreased expression of the GIPR gene in subcutaneous fat tissue is associated with signs of insulin resistance in non-diabetic women with central obesity and demonstrates that fasting hyperinsulinemia is a possible negative regulator of GIPR gene expression in subcutaneous fat. Higher GIPR gene expression levels in visceral fat vs. subcutaneous fat reflect regional differences in adipose tissue biology. Moderate weight reduction did not change gene expression levels of GIPR in subcutaneous fat.
AIMS: Gastric inhibitory polypeptide (GIP) is an insulinotropic duodenal hormone released in response to meals. Recent studies in rodents suggested that GIP directly links overnutrition to obesity. Despite evidence for GIP effects on fat metabolism in humans, the GIP receptor (GIPR) has not been identified in fat tissues. We identified the GIPR gene in human subcutaneous and visceral fat tissues and tested the hypothesis that that the expression of this gene is influenced by central obesity and weight loss. METHODS:GIPR gene mRNA expression in subcutaneous fat tissue biopsies (n=70) and in paired subcutaneous and visceral fat tissue samples (n=25) of non-diabetic postmenopausal women was studied by real-time reverse transcription polymerase chain reaction. The effect of weight reduction on GIPR gene expression in subcutaneous fat tissue was studied in a subset of 14 women. RESULTS:GIPR adipose tissue gene expression was significantly lower in insulin resistant obese non-diabeticwomen (p=0.004). The GIPR mRNA expression was higher in the visceral fat tissue compared with subcutaneous fat (p<0.001). Despite adjustment for obesity-associated variables, waist circumference was the most significant predictor of GIPR gene expression in subcutaneous fat depot (F=4.066; beta=-0.997; p=0.0001) and, together with fasting insulin levels, in visceral fat (F=3.553; beta=-0.507 and beta=0.495; p=0.0001). Moderate weight reduction did not change gene expression levels of the GIPR gene (p=0.085). CONCLUSIONS: Decreased expression of the GIPR gene in subcutaneous fat tissue is associated with signs of insulin resistance in non-diabeticwomen with central obesity and demonstrates that fasting hyperinsulinemia is a possible negative regulator of GIPR gene expression in subcutaneous fat. Higher GIPR gene expression levels in visceral fat vs. subcutaneous fat reflect regional differences in adipose tissue biology. Moderate weight reduction did not change gene expression levels of GIPR in subcutaneous fat.
Authors: Özlem Gögebakan; Martin A Osterhoff; Rita Schüler; Olga Pivovarova; Michael Kruse; Anne-Cathrin Seltmann; Alexander S Mosig; Natalia Rudovich; Michael Nauck; Andreas F H Pfeiffer Journal: Diabetologia Date: 2015-05-21 Impact factor: 10.122
Authors: Ricardo J Samms; Michael E Christe; Kyla Al Collins; Valentina Pirro; Brian A Droz; Adrienne K Holland; Jessica L Friedrich; Samantha Wojnicki; Debra L Konkol; Richard Cosgrove; Ellen Ps Conceição Furber; Xiaoping Ruan; Libbey S O'Farrell; Annie M Long; Mridula Dogra; Jill A Willency; Yanzhu Lin; Liyun Ding; Christine C Cheng; Over Cabrera; Daniel A Briere; Jorge Alsina-Fernandez; Ruth E Gimeno; Julie S Moyers; Tamer Coskun; Matthew P Coghlan; Kyle W Sloop; William C Roell Journal: J Clin Invest Date: 2021-06-15 Impact factor: 14.808
Authors: Jonathan E Campbell; Jacqueline L Beaudry; Berit Svendsen; Laurie L Baggio; Andrew N Gordon; John R Ussher; Chi Kin Wong; Fiona M Gribble; David A D'Alessio; Frank Reimann; Daniel J Drucker Journal: Diabetes Date: 2022-05-01 Impact factor: 9.337
Authors: Özlem Gögebakan; Janin Andres; Katrin Biedasek; Knut Mai; Peter Kühnen; Heiko Krude; Frank Isken; Natalia Rudovich; Martin A Osterhoff; Ulrich Kintscher; Michael Nauck; Andreas F H Pfeiffer; Joachim Spranger Journal: Diabetes Date: 2011-12-16 Impact factor: 9.461